Opendata, web and dolomites

RSVTriVax SIGNED

Development of a trivalent epitope-focused RSV vaccine to boost pre-existing immunity

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 RSVTriVax project word cloud

Explore the words cloud of the RSVTriVax project. It provides you a very rough idea of what is the project "RSVTriVax" about.

elicited    compelling    cutting    million    viral    close    functional    molecular    candidates    abs    animal    eliciting    competitive    mechanisms    world    children    elderly    iuml    pathogen    attributed    health    young    vaccine    deemed    causes    clinically    human    carries    public    virus    ve    molecules    commercial    deaths    financial    protect    approved    tools    profile    potent    organization    sophisticated    trivax    natural    prevent    manufacturing    protective    epitopes    model    exquisite    pregnant    33    stable    showed    candidate    thereby    neutralization    primary    induction    promise    rsv    boosting    alternative    edge    strongest    neutralizing    preliminary    episodes    immune    intensive    populations    mimicking    safety    cocktail    superior    good    burdens    infants    immunogens    syncytial    primates    subdominant    protection    global    boost    respiratory    annually    epitope    scenario    cohort    yield    infection    120    antibodies    na    globally    women    decades    consolidate    emerge    infections    suggesting    formulation    societal    mostly    competitor   

Project "RSVTriVax" data sheet

The following table provides information about the project.

Coordinator
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE 

Organization address
address: BATIMENT CE 3316 STATION 1
city: LAUSANNE
postcode: 1015
website: www.epfl.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) coordinator 150˙000.00

Map

 Project objective

The development of a Respiratory Syncytial Virus (RSV) vaccine is deemed a global health priority by the World Health Organization. Globally, RSV causes 33 million episodes of infection and up to 120,000 deaths annually. The most affected populations are pre-term infants, young children and the elderly. Several decades of intensive research are yet to yield a clinically approved vaccine. This failure is mostly attributed to sophisticated viral mechanisms that prevent the induction of protective antibodies (Abs). Using cutting-edge molecular design tools, we developed a novel vaccine candidate (TriVax) to focus immune responses in such key neutralization epitopes. TriVax is a cocktail composed of three epitope-focused immunogens mimicking three distinct neutralization epitopes targeted by potent neutralizing Abs. Our primary target populations are pregnant women (protection of pre-term infants) and elderly, where the challenge is to boost subdominant, neutralizing Abs elicited during previous natural infections. Recently, we showed that epitope-focused immunogens are exquisite at boosting subdominant functional Abs, and in this scenario, superior to the strongest competitor vaccine candidates. In a preliminary study in Non-Human Primates, TriVax showed great promise by eliciting robust neutralization on an RSV naïve cohort, suggesting a good safety profile and the potential to emerge as a competitive alternative for vaccine development. For manufacturing, epitope-focused immunogens are simple and stable molecules that can be produced at low cost. Overall, we propose a viable vaccine formulation to protect against an important pathogen which carries large financial burdens on public health systems. Thus, our proposal has an important societal and financial impact, and will provide compelling evidence for Trivax to boost neutralizing Abs in a close-to-human animal model, thereby taking an essential step to consolidate the commercial potential of our vaccine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RSVTRIVAX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RSVTRIVAX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

OBSERVE (2020)

Overcoming cellular barriers to therapeutic RNA delivery using extracellular vesicles

Read More  

SuperH (2019)

Discovery and Characterization of Hydrogen-Based High-Temperature Superconductors

Read More  
lastchecktime (2022-05-23 6:01:27) correctly updated